Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRONKOMETER vs AEROLATE III
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Treatment of bronchial asthma,Reversible bronchospasm associated with bronchitis and emphysema
Treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, and emphysema,Off-label: Apnea of prematurity (oral/IV theophylline)
Isoetharine mesylate 0.5% solution: 2-4 inhalations every 4 hours as needed via hand-held nebulizer or IPPB.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
Terminal elimination half-life: 2-3 hours; clinically, bronchodilation persists but dosing interval is 3-4 hours due to rapid onset and offset.
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Metabolized by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO).
Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics.
Renal: 10-15% unchanged; 70-80% as sulfate conjugates; biliary/fecal: <5%.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
50-60% bound primarily to albumin.
92-96%, primarily to albumin and alpha-1-acid glycoprotein
Vd: 1-2 L/kg; indicates extensive distribution into tissues including lungs.
Vd 1.5-2.0 L/kg, indicating extensive tissue distribution
Aerosol: 10-20% lung deposition; remainder swallowed with negligible oral bioavailability due to first-pass metabolism.
Oral: 40-50%; Inhalation: 20-30%
No specific dose adjustment required based on GFR; clinical monitoring advised in severe renal impairment due to potential for drug accumulation.
No adjustment needed for GFR >30 m L/min. For GFR 10-30 m L/min: use 50% of usual dose. For GFR <10 m L/min: avoid use.
No formal Child-Pugh based modifications established; caution in severe hepatic impairment due to possible altered metabolism.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Children 6-12 years: 1-2 inhalations every 4 hours as needed; <6 years: not recommended due to limited data.
Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult.
Initiate at lower end of dosing range (1-2 inhalations every 4 hours as needed) due to increased sensitivity and concomitant comorbidities; monitor for adverse cardiovascular effects.
No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose.
No FDA black box warning.
No FDA black box warning.
Paradoxical bronchospasm may occur,Cardiovascular effects including increased heart rate and blood pressure,Hypokalemia may occur,Use with caution in patients with cardiovascular disorders, hyperthyroidism, diabetes, or seizure disorders,Excessive use may lead to tolerance
Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/m L; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others.
Hypersensitivity to isoetharine or any component,Pre-existing cardiac arrhythmias associated with tachycardia
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may increase cardiac stimulation. No specific food restrictions, but a balanced diet is recommended. Avoid alcohol as it may worsen side effects.
Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake.
Insufficient human data; animal studies show no teratogenic effects at clinically relevant doses. Risk cannot be excluded; use only if clearly needed.
AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/m L). Avoid near term due to prolonged neonatal half-life.
Unknown whether isoproterenol or its metabolites are excreted in human milk. Caution advised; weigh risks vs benefits. M/P ratio not available.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity.
No specific dose adjustments recommended; pharmacokinetic changes in pregnancy may alter response, requiring titration to effect.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased renal blood flow. Dose adjustments are often required: monitor serum levels regularly and adjust dose to maintain therapeutic levels. Typically, dose may need to be increased by 20-50% in second and third trimesters.
Bronkometer contains isoetharine, a beta-2 selective agonist, but less selective than albuterol. It is rarely used now due to higher cardiac side effect risk. Monitor for paradoxical bronchospasm; discontinue if occurs. Use with caution in patients with hyperthyroidism, diabetes, or hypertension.
AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias.
Shake the inhaler well before each use.,Prime the inhaler by spraying 4 test sprays into the air away from face if new or not used for 3 days.,Exhale fully, then place mouthpiece in mouth and inhale slowly while pressing down on canister.,Hold breath for 10 seconds, then exhale slowly.,Wait at least 1 minute between puffs.,Rinse mouth with water after use to prevent mouth irritation.,Seek emergency care if you experience worsening shortness of breath, chest pain, or irregular heartbeat.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia.,Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures.,Do not stop taking this medication abruptly; taper under medical supervision.,Keep all appointments for blood tests to monitor theophylline levels.,Avoid smoking or using nicotine products, as they affect how the medication works.,Carry a list of all medications you take, as many can interact with theophylline.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRONKOMETER vs AEROLATE III, answered by our medical review team.
BRONKOMETER is a Bronchodilator that works by Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.. AEROLATE III is a Bronchodilator that works by AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRONKOMETER and AEROLATE III depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRONKOMETER is: Isoetharine mesylate 0.5% solution: 2-4 inhalations every 4 hours as needed via hand-held nebulizer or IPPB.. The standard adult dose of AEROLATE III is: Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRONKOMETER and AEROLATE III in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRONKOMETER is classified as Category C. Insufficient human data; animal studies show no teratogenic effects at clinically relevant doses. Risk cannot be excluded; use only if clearly needed.. AEROLATE III is classified as Category C. AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.